Astera Labs Trading Volume Plummets 48.14% Ranking 106th Despite Jefferies Bullish Outlook

Generated by AI AgentAinvest Volume Radar
Tuesday, Jul 22, 2025 6:50 pm ET1min read
ALAB--
Aime RobotAime Summary

- Astera Labs (ALAB) saw 48.14% lower trading volume on July 22, 2025, with 8.72B shares traded and a 4.09% stock price decline.

- Jefferies raised ALAB's price target to $130 from $95, maintaining "Buy" rating, citing expected Scorpio X/Trn4 product launches and 2026-2027 growth.

- Analysts project 2027 EPS at $2.81 (up from $2.32) and note 2026 estimates already exceed consensus, signaling strong long-term confidence despite short-term trading weakness.

On July 22, 2025, AsteraALAB-- Labs (ALAB) experienced a significant decline, with its trading volume dropping by 48.14% to 8.72 billion, ranking 106th in the day's market activity. The stock price of Astera Labs fell by 4.09%.

Jefferies has raised its price target for Astera Labs (ALAB) to $130 from $95, while maintaining a "Buy" rating. This adjustment reflects a bullish outlook on the company's future performance, particularly in the second half of 2026. The firm anticipates that Astera will supply Scorpio X for scale-up in Trainium 3 and introduce a new UAL switch for Trn4, which could drive significant growth. Additionally, JefferiesJEF-- has increased its calendar 2027 EPS forecast to $2.81 from $2.32, indicating strong confidence in Astera's long-term prospects.

Analyst Blayne Curtis from Jefferies highlights that the firm's estimates for calendar 2026 are already above the consensus, suggesting that Astera Labs is poised for substantial upside. The optimistic earnings scenario by 2027, coupled with increased content assumptions across Trainium platforms, further supports the positive outlook for the company.

Encuentra las acciones con volumen de negociación explosivo.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet